The future of the global ventricular assist device market looks promising with opportunities in the bridge-to-transplant, destination therapy, bridge-to-recovery, and bridge to candidacy therapy applications. The global ventricular assist device market is expected to reach an estimated $3.2 billion by 2030 with a CAGR of 10.5% from 2024 to 2030. The major drivers for this market are rising prevalence of heart failure and growing number of patients with cardiovascular disease.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the ventricular assist device
market by design (transcutaneous ventricular assist devices and implantable
ventricular assist devices), product (left ventricular assist devices, right
ventricular assist devices, and biventricular assist devices), application
(bridge-to-transplant, destination therapy, bridge-to-recovery, and bridge to
candidacy therapy), end use (ambulatory surgery centers, hospital, and others),
and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will
grow at a faster pace and why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the
emerging trends in this market and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the
industry?
Market Segmentation:
In this market,
transcutaneous ventricular assist device and implantable ventricular assist
device are the major segments of ventricular assist device market by design.
Lucintel forecasts that implantable ventricular assist device is expected to
witness the higher growth over the forecast period due to its rising usage
among patients with heart issue to improve the pumping function of the
heart.Within this market, destination therapy is expected to witness the
highest growth.
North America is
expected to witness highest growth over the forecast period due to existence of
strong healthcare system and presence of key players in the region.
Abbott Laboratories,
Corewave, Bivacor, Carmat, and Jarvik Heart are the major suppliers in the
ventricular assist device market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Explore Our Latest Publications
No comments:
Post a Comment